FMDs, when combined with antibodies targeting PD-L1 and the co-stimulatory molecule OX40 (CD134), further amplify effector T-cell infiltration, suppress regulatory T-cells, and upregulate CD127 expression, thus sustaining anti-tumor activity [146]. This evidence concerns the gene TNFRSF4 and neoplasm.